Cargando…

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387311/ https://www.ncbi.nlm.nih.gov/pubmed/32060403 http://dx.doi.org/10.1038/s41375-020-0743-y

Ejemplares similares

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab
por: Morcos, Peter N., et al.
Publicado: (2023)

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
por: Cheson, Bruce D., et al.
Publicado: (2018)

Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
por: Patnaik, A., et al.
Publicado: (2016)

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers
por: Gerisch, Michael, et al.
Publicado: (2017)

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
por: Morcos, Peter N., et al.
Publicado: (2023)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018)

Validated HPLC method for quantification of copanlisib in mice plasma: application to a pharmacokinetic study
por: Zakkula, Ashok, et al.
Publicado: (2020)

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling
por: AlRabiah, Haitham, et al.
Publicado: (2019)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer
por: Yan, Ji, et al.
Publicado: (2020)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
por: Fang, Bin, et al.
Publicado: (2020)

Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials
por: Wang, Jinjin, et al.
Publicado: (2022)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

FLT PET-CT in evaluation of treatment response
por: Sanghera, Bal, et al.
Publicado: (2014)

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication
por: Delang, Leen, et al.
Publicado: (2012)

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)
por: Scott, William J., et al.
Publicado: (2016)

Phosphatidylinositol-4-Phosphate 5-Kinases and Phosphatidylinositol 4,5-Bisphosphate Synthesis in the Brain
por: Volpicelli-Daley, Laura A., et al.
Publicado: (2010)

The PITP family of phosphatidylinositol transfer proteins
por: Hsuan, Justin, et al.
Publicado: (2001)

Phosphatidylinositol signalling defects implicated in IBD
Publicado: (2014)

Structural basis for phosphatidylinositol-phosphate biosynthesis
por: Clarke, Oliver B., et al.
Publicado: (2015)

Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica
por: Nakada-Tsukui, Kumiko, et al.
Publicado: (2019)

Foot-and-mouth disease virus replicates independently of phosphatidylinositol 4-phosphate and type III phosphatidylinositol 4-kinases
por: Berryman, Stephen, et al.
Publicado: (2016)

Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin’s and Diffuse Large B Cell Lymphomas
por: Latifoltojar, Arash, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mdqrgrtaccg0a9qo1lkpu332hp